Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
By L. Bolondi, Andrew K. Burroughs, J. Dufour, Peter R. Galle, V. Mazzaferro, F. Piscaglia, J. Raoul, B. Sangro. Seminars in liver disease (Print), 2012
653 citations recorded by the source corpus.
Abstract The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly heterogeneous patient population and therefore poses unique challenges for therapeutic management, different from the early and advanced stages. Patients classified as having intermediate HCC by the Barcelona Clinic Liver Cancer (BCLC) staging system present with varying tumor burden and liver function. Transarterial chemoembolization (TACE) is currently recommended as the standard of care in this setting, but there is considerable variation in the clinical benefit patients derive from this treatment. In April 2012, a panel of experts convened to discuss unresolved issues surrounding the application of current guidelines when managing patients with intermediate HCC. The meeting explored the applicability of a subclassification system for intermediate HCC patients to tailor therapeutic interventions based on the evidence available to date and expert opinion. The present report summarizes the proposal of the expert panel: four substages of intermediate HCC patients, B1 to B4.
Subfields: Hepatology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/4405a06c574d7bcaa50d74229e4b02162d567e0f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- J. Llovet
- V. Mazzaferro
- Alejandro Forner1 , 2
- Peter R. Galle
- F. Piscaglia
- J. Raoul
- V. Vilgrain
- P. Schirmacher
In Oncology
Citations in the corpus
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “This has triggered a major controversy and willingness to further stratify the BCLC-B category according to tumour burden and liver function.(316,317) Some of these proposals classify large solitary HCC beyond 5 cmwith an expansive growth as intermediate-stage, although vascular invasion or tumour d”